Hansa Biopharma has announced positive data from the European Post‑Authorization Efficacy and Safety study of Idefirix, ...
Hutchmed has announced positive phase 3 results from the SANOVO trial evaluating ORPATHYS plus TAGRISSO in treatment‑naïve ...
Patients with oligometastatic non‑small cell lung cancer lived significantly longer without disease progression when radiotherapy was added to standard systemic therapy, according to new phase 2 data ...
The FDA has approved GSK’s Hibsago for adults with chronic hepatitis B virus infection who meet specific virological criteria ...
Microbiotica has presented new phase 1b clinical data for MB097, its oral precision microbiome therapeutic for advanced ...
Johnson & Johnson has secured European Commission approval for an indication extension of teclistamab monotherapy for adults ...
The FDA has approved Genentech’s Enspryng for adults with thyroid eye disease, making it the first at‑home subcutaneous ...
Sitryx Therapeutics has announced positive topline phase 1b results for SYX-5219, a first-in-class oral PKM2 modulator being ...
ViiV Healthcare has signed an agreement appointing Axmed as a non-exclusive distributor to support procurement and supply of ...
Johnson & Johnson has announced that the CHMP recommends approval of an indication extension for TALVEY (talquetamab) plus ...
Merz Therapeutics has completed patient recruitment in two global phase 3 trials evaluating XEOMIN (incobotulinumtoxinA) for ...
Osivax has reported phase 2b results for OVX836 and outlined the next stage of development for its next-generation seasonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results